AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8526243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day for 5 weeks
Number of subjects: 68
Study 8526243 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 68
Study 2405792 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 40
Study 2405792 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 40
Study 511533 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril) 1 mg per day
Number of subjects: 38
Study 511533 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril) 2 mg per day
Number of subjects: 38
Study 511533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30670421 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg levofloxacin dispersible tablets
Number of subjects: 133
Study 30670421 — intervention group
Group type: COMPARATOR
Intervention: Adult (250-mg) levofloxacin tablets
Number of subjects: 133
Study 28157380 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2g/day)
Number of subjects: 95
Study 28157380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mainly oleic and linoleic acid)
Number of subjects: 95
Study 26145489 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback‐based virtual reality exercise (IFVRG)
Number of subjects: 54
Study 26145489 — intervention group
Group type: COMPARATOR
Intervention: Group-based exercise (GG)
Number of subjects: 54
Study 26145489 — intervention group
Group type: COMPARATOR
Intervention: Both groups (IFVRG and GG)
Number of subjects: 54
Study 23428998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 647
Study 23428998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase in patients with baseline body temperature of 37.0°C or higher
Number of subjects: 647
Study 23428998 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase in patients with baseline body temperature below 37.0°C
Number of subjects: 647
Study 20806420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 43
Study 20001460 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 19
Study 17320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 17320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vitamin D metabolites (calcitriol)
Number of subjects: 0
Study 17320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapy initiated in the immediate posttransplantation period
Number of subjects: 0
Study 17320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mass measurement and treatment of osteoporosis
Number of subjects: 0
Study 17320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral or parenteral bisphosphonates and calcitriol
Number of subjects: 0
Study 15314341 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation reduction program (experimental group)
Number of subjects: 61
Study 15314341 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 61
Study 11501230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (Crestor); specific dosage and duration not mentioned.
Number of subjects: 0
Study 11501230 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group not mentioned.
Number of subjects: 0
Study 9386697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning (two cycles of 2-minute occlusion of the vena cava and aorta followed by 3 minutes of reperfusion)
Number of subjects: 30
Study 9386697 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning
Number of subjects: 30
Study 9386697 — intervention group
Group type: COMPARATOR
Intervention: Control (no preconditioning)
Number of subjects: 30
Study 8143996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg, three times daily
Number of subjects: 42
Study 8143996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg, three times daily
Number of subjects: 42
Study 8143996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (both doses)
Number of subjects: 42
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with T cell ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with non-T cell ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with early pre-B ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with pre-B ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with T ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with non-T, non-B ALL
Number of subjects: 425
Study 3422091 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with leukemic cells
Number of subjects: 425
Study 30188180 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative algorithm for diabetes management during Ramadan
Number of subjects: 62
Study 30188180 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 62
Study 28328389 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based hearing screening method
Number of subjects: 30
Study 28328389 — intervention group
Group type: COMPARATOR
Intervention: Conventional audiometry
Number of subjects: 30
Study 26203761 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 258
Study 26203761 — intervention group
Group type: COMPARATOR
Intervention: CRT + cetuximab
Number of subjects: 258
Study 23885614 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenshu (BL 23) and Guanyuan (CV 4) for 15 min once daily for 5 weeks after training.
Number of subjects: 24
Study 23885614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no moxibustion).
Number of subjects: 24
Study 20958974 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic powder tablets)
Number of subjects: 51
Study 17662639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric calf muscle training
Number of subjects: 16
Study 17662639 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 16
Study 16647533 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori presence in the middle ear, tonsillar and adenoid tissues
Number of subjects: 22
Study 16647533 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal otologic findings)
Number of subjects: 22
Study 14655264 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer
Number of subjects: 18
Study 14655264 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch Biographer (if ceased to be effective after age 17)
Number of subjects: 18
Study 10985062 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-selective thyrotoxicosis (19 patients)
Number of subjects: 33
Study 10985062 — intervention group
Group type: COMPARATOR
Intervention: Subclinical thyrotoxicosis (14 patients)
Number of subjects: 33
Study 8834417 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (mean dose, 7.4 mg/day)
Number of subjects: 62
Study 8834417 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (7.6 mg/day)
Number of subjects: 62
Study 8834417 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrimeprazine (100 mg/day)
Number of subjects: 62
Study 8834417 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 62
Study 8834417 — intervention group
Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 62
Study 1573365 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking advice (intervention)
Number of subjects: 1445
Study 1573365 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 1445
Study 6363970 — intervention group
Group type: EXPERIMENTAL
Intervention: Central anticholinergic therapy
Number of subjects: 9
Study 6363970 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral anticholinergic therapy
Number of subjects: 9
Study 6363970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6363970 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (peripheral anticholinergic)
Number of subjects: 9
Study 31395071 — intervention group
Group type: EXPERIMENTAL
Intervention: MR technology-assisted group (group A)
Number of subjects: 40
Study 31395071 — intervention group
Group type: COMPARATOR
Intervention: Traditional C-arm fluoroscopy group (group B)
Number of subjects: 40
Study 30094695 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 699
Study 30094695 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 699
Study 30094695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Methadone and Buprenorphine/Naloxone)
Number of subjects: 699
Study 30094695 — intervention group
Group type: COMPARATOR
Intervention: Cocaine users and injection drug users
Number of subjects: 699
Study 30094695 — intervention group
Group type: COMPARATOR
Intervention: Hispanics (vs. whites) and those treated in clinics on the West Coast (vs. East)
Number of subjects: 699
Study 27094111 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 746
Study 27094111 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 746
Study 25617577 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of alpha lipoic acid (ALA) for twelve weeks
Number of subjects: 60
Study 25617577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of albuminuria and estimated glomerular filtration rate (eGFR) for CKD diagnosis
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific chronic nephropathy
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetermined chronic nephropathy
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD Stages 1, 2, 3, and 4
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lone low eGFR and lone microalbuminuria
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR and albuminuria
Number of subjects: 524
Study 21737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up studies
Number of subjects: 524
Study 19337246 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal capsule endoscopy (ECE)
Number of subjects: 120
Study 19337246 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 120
Study 17786387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP infusions at doses of 20 microg kg(‐1) min(‐1), 25-40 microg kg(‐1) min(‐1), and 45-50 microg kg(‐1) min(‐1)
Number of subjects: 51
Study 15612969 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified trivalent split-virus vaccine injections
Number of subjects: 125
Study 15612969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 11642001 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise program
Number of subjects: 0
Study 9853844 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant follicle stimulating hormone (rFSH, Puregon)
Number of subjects: 89
Study 9853844 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG, Humegon)
Number of subjects: 89
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil New Bond
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripton
Number of subjects: 346
Study 7983255 — intervention group
Group type: COMPARATOR
Intervention: Bayer exp. 1
Number of subjects: 346
Study 7983255 — intervention group
Group type: COMPARATOR
Intervention: Bayer exp. 2
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond System
Number of subjects: 346
Study 7983255 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 346
Study 2904312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg every 8 hours)
Number of subjects: 6
Study 2904312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (5 mg every 8 hours)
Number of subjects: 6
Study 2904312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30402489 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin
Number of subjects: 45
Study 30402489 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 45
Study 27344670 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM application at the donor site using a 60 J/cm(2) dose
Number of subjects: 51
Study 27344670 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM application using a 30 J/cm(2) dose
Number of subjects: 51
Study 27344670 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 51
Study 25050827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise condition (PACER task, aerobic fitness assessment)
Number of subjects: 0
Study 25050827 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment)
Number of subjects: 0
Study 21856022 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 36
Study 21856022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21903567 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive systems with different dentin conditioning times; groups divided based on conditioning time and adhesive system used (n = 10 per group).
Number of subjects: 60
Study 18173628 — intervention group
Group type: EXPERIMENTAL
Intervention: Near pupil responses (NPR) classified as normal, reduced, or absent
Number of subjects: 90
Study 18173628 — intervention group
Group type: EXPERIMENTAL
Intervention: NPR
Number of subjects: 90
Study 16602839 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (3 x 2 g/d)
Number of subjects: 105
Study 16602839 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 12588573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including staff and resident education on fall prevention, advice on environmental adaptations, progressive balance and resistance training, and hip protectors
Number of subjects: 981
Study 12588573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 981
Study 10913939 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (40 U/kg at a constant infusion rate for 30 min, starting 15 min before TRH injection)
Number of subjects: 16
Study 10913939 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO plus TRH
Number of subjects: 16
Study 10913939 — intervention group
Group type: COMPARATOR
Intervention: rhEPO
Number of subjects: 16
Study 10913939 — intervention group
Group type: COMPARATOR
Intervention: TRH
Number of subjects: 16
Study 9044441 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement treatment
Number of subjects: 38
Study 9044441 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 38
Study 9044441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9044441 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin
Number of subjects: 38
Study 1573788 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy with extended lymph node dissection
Number of subjects: 0
Study 1573788 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastrectomy
Number of subjects: 0
Study 4054198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclonazepam 1 mg
Number of subjects: 0
Study 4054198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclonazepam 2 mg
Number of subjects: 0
Study 4054198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclonazepam 4 mg
Number of subjects: 0
Study 4054198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30867552 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine dependence (SCD)
Number of subjects: 25
Study 30867552 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 30867552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflated cocaine addiction
Number of subjects: 25
Study 29847145 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted repair of the medial patellofemoral ligament (MPFL) with anchors, 4 weeks with a soft cast splint, and physical therapy
Number of subjects: 74
Study 29847145 — intervention group
Group type: COMPARATOR
Intervention: Knee brace (KB group) for 4 weeks and physical therapy
Number of subjects: 74
Study 29847145 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic‐assisted repair of the medial patellofemoral ligament (MPFL)
Number of subjects: 74
Study 29847145 — intervention group
Group type: COMPARATOR
Intervention: Knee brace (KB group)
Number of subjects: 74
Study 27181790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide (BMT) 1.25/1.75 mg
Number of subjects: 327
Study 27181790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 24835837 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) screening (left hand, right hand, feet)
Number of subjects: 26
Study 21447539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion + education for internet use (EDU)
Number of subjects: 50
Study 21447539 — intervention group
Group type: COMPARATOR
Intervention: Placebo + education for internet use (EDU)
Number of subjects: 50
Study 20075367 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized biomarker-stratified designs
Number of subjects: 0
Study 18823468 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120
Study 18823468 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study 16600937 — intervention group
Group type: EXPERIMENTAL
Intervention: [6S]-5-Methyltetrahydrofolate (416 microg/d)
Number of subjects: 72
Study 16600937 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (400 microg/d)
Number of subjects: 72
Study 16600937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 14684754 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanders strain of flax seed (low in lignan and high in alpha-linolenic acid)
Number of subjects: 35
Study 14684754 — intervention group
Group type: EXPERIMENTAL
Intervention: Linola 989 strain of flax seed (high in lignan and low in alpha-linolenic acid)
Number of subjects: 35
Study 14684754 — intervention group
Group type: EXPERIMENTAL
Intervention: AC Linora strain of flax seed (intermediate in both lignan and alpha-linolenic acid)
Number of subjects: 35
Study 10760553 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 0
Study 10760553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysthymic patients
Number of subjects: 0
Study 10760553 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive patients
Number of subjects: 0
Study 8814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 700 mg/day
Number of subjects: 12
Study 8814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 600 mg/day
Number of subjects: 12
Study 8814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 500 mg/day
Number of subjects: 12
Study 8814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day
Number of subjects: 12
Study 8814098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study 8814098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1306479 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser pan retinal photocoagulation
Number of subjects: 0
Study 1306479 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser pan retinal photocoagulation
Number of subjects: 0
Study 1306479 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 0
Study 2997092 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone for six days)
Number of subjects: 60
Study 2997092 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid therapy
Number of subjects: 60
Study 30246214 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyolefin cast
Number of subjects: 80
Study 30246214 — intervention group
Group type: COMPARATOR
Intervention: Fibreglass cast
Number of subjects: 80
Study 28943228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 423
Study 28943228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 25683105 — intervention group
Group type: COMPARATOR
Intervention: 100% portion size (677 kcal)
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% portion size (1015 kcal)
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: 200% portion size (1353 kcal)
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: 250% portion size (1691 kcal)
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: Food responsiveness
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety responsiveness
Number of subjects: 100
Study 25683105 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight status
Number of subjects: 100